Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658982 | 0.89 | HDAC3 (0.46) | HDAC6HDAC1HDAC2HDAC4HDAC3 | |
| SCHEMBL7066667 | 0.86 | HDAC1 (0.37) | HDAC6HDAC1HDAC2HDAC4HDAC3 | |
| SCHEMBL5659484 | 0.68 | ADORA2B (0.38) | HDAC6HDAC1HDAC4NPC1ADORA3 | |
| SCHEMBL5999067 | 0.63 | ALDH1A1 (0.40) | HDAC6HDAC1HDAC4NPC1ALDH1A1 | |
| SCHEMBL2054791 | 0.60 | HSP90AB1 (0.52) | HDAC6HDAC1HDAC4 | |
| SCHEMBL30881639 | 0.60 | NR1H4 (0.57) | HDAC6HDAC1HDAC2HDAC4HDAC3 | |
| SCHEMBL29601580 | 0.60 | P2RX7 (0.48) | HDAC6HDAC1HDAC2HDAC4HDAC3 | |
| SCHEMBL1355050 | 0.60 | P2RX7 (0.48) | HDAC6HDAC1HDAC2HDAC4HDAC3 | |
| SCHEMBL7875548 | 0.59 | KCNMA1 (0.47) | HDAC1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL655757 | 0.59 | MITF (0.53) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | PITTS WILLIAM J | 2006-09-28 | — | — | US | disclosed |
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-12 | — | — | US | disclosed |
| WO-2004106293-A2 | OXAZOLYL - AND THIAZOLYL - PURINE BASED TRICYCLIC COMPOUNDS. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101626-A1 | Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | HDAC6 971/4885HDAC1 304/4885HDAC2 583/4885 |
| US-20060217412-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | HDAC6 780/4885HDAC1 287/4885HDAC2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.